Across 217 unique CTIS lymphoma Phase II–III trials in Europe, 98 trials used at least one CRO or outsourced clinical-trial support provider, equal to 45.2%. CRO use concentrates sharply in operationally complex trials: 35/39 trials with 7+ countries used CROs, and 18/21 trials with 51+ sites used CROs. IQVIA was the most frequently listed provider, supporting 33/98 CRO-supported trials, followed by ICON and PPD with 27 trials each.
Phase III lymphoma trials had a CRO utilization rate of 41/66 trials (62.1%), compared with 53/144 Phase II trials (36.8%). The Phase II/III overlap cohort sat between them at 4/7 trials (57.1%).
Late-stage lymphoma development creates the strongest outsourcing signal. CRO involvement becomes more common when the trial is designed for confirmatory evidence generation, broader site activation, and coordinated CTIS/EU country submissions.
Among the 98 CRO-supported lymphoma trials, IQVIA appeared in 33 trials (33.7%), ICON in 27 trials (27.6%), and PPD in 27 trials (27.6%). Almac and Parexel followed with 18 and 17 CRO-supported trials, respectively.
The top providers mix full-service CROs and specialist infrastructure vendors. This suggests lymphoma outsourcing is not only about full trial execution; sponsors also repeatedly externalize eClinical systems, central labs, imaging, supply, and country-level operational support.
Trials listing 7+ countries had the highest CRO utilization: 35/39 trials (89.7%). CRO use was much lower in single-country trials, where only 12/80 trials (15.0%) listed CRO support.
Country count is the clearest operational threshold in this cohort. Once a lymphoma trial crosses into broad multi-country CTIS submission and Part II coordination, CRO support shifts from optional to structurally common.
Trials with 51+ sites used CROs in 18/21 cases (85.7%). CRO use was materially lower in smaller footprints: 21/61 trials (34.4%) with 1–10 sites and 26/81 trials (32.1%) with 11–25 sites used CRO support.
Site activation and site management appear to be major outsourcing triggers. The utilization jump above 50 sites indicates that CROs are most needed when country-level approval, site start-up, monitoring, and operational tracking become too distributed for internal teams alone.
CRO utilization peaked at 23/32 trials (71.9%) in the 151–300 participant band. Smaller trials had similar CRO rates, with 27/74 trials (36.5%) in the 1–50 participant range and 30/84 trials (35.7%) in the 51–150 participant range.
Participant count alone is a weaker outsourcing trigger than countries or sites. The strongest signal is mid-to-large evidence generation, where enrollment is large enough to require structured operations but not necessarily dominated by single-country academic megatrials.
DLBCL / large B-cell lymphoma generated the largest absolute CRO workload with 33/70 trials (47.1%). CLL/SLL had the highest CRO utilization among larger indications, with 27/43 trials (62.8%). Hodgkin lymphoma and follicular lymphoma followed with 25 and 20 CRO-supported trials, respectively.
DLBCL drives the largest CRO volume because it appears across many Phase II–III programs. CLL/SLL is the more outsourcing-intensive major indication, likely reflecting larger multi-country CTIS programs and commercial late-stage development intensity.
Among 98 CRO-supported trials, 89 trials (90.8%) listed full-service CRO, trial operations, monitoring, or country execution support. Central lab, biomarker, or sample services appeared in 49/98 trials (50.0%), while eClinical, data, CTMS, IVRS/IxRS or platform support appeared in 48/98 trials (49.0%).
The outsourcing stack is broad: operational CRO support dominates, but roughly half of CRO-supported lymphoma trials also externalize lab/biomarker workflows or eClinical infrastructure. For CTIS/EU submissions, this matters because vendor roles are often tied to country operations, data capture, randomization, supply, and safety workflows.
Spain appeared in 66 CRO-supported trial-country entries out of 99 lymphoma trial-country entries (66.7%). France followed with 60/91 (65.9%), Italy with 59/102 (57.8%), and both Poland and Germany with 50 CRO-supported trial-country entries each.
| Country | CRO trials | CRO rate | CRO sites | CRO participants |
|---|---|---|---|---|
| Spain | 66/99 | 66.7% | 486 | 1999 |
| France | 60/91 | 65.9% | 517 | 2331 |
| Italy | 59/102 | 57.8% | 422 | 1648 |
| Poland | 50/61 | 82.0% | 272 | 1790 |
| Germany | 50/75 | 66.7% | 335 | 965 |
| Belgium | 36/57 | 63.2% | 111 | 442 |
| Czechia | 33/37 | 89.2% | 98 | 745 |
| Denmark | 29/49 | 59.2% | 63 | 460 |
| Netherlands | 25/42 | 59.5% | 117 | 517 |
| Austria | 24/31 | 77.4% | 58 | 255 |
Large Western European markets remain core CRO operating territory, but Poland and Czechia show particularly high CRO rates: Poland had 50/61 CRO-supported entries (82.0%) and Czechia had 33/37 (89.2%). For EU submission planning, these countries look especially CRO-dependent in lymphoma Phase II–III programs.
Pharma and biotech sponsors used CRO support in 86/115 lymphoma Phase II–III trials (74.8%). Academic sponsors used CROs in 5/11 trials (45.5%), while hospital or healthcare sponsors used CROs in only 6/53 trials (11.3%).
Sponsor type is one of the strongest adjacent predictors of CRO use. Commercial sponsors are far more likely to formalize CRO/vendor roles for CTIS/EU submissions, while investigator-led and hospital-led lymphoma studies often rely on internal or network-based operations.
Bispecific antibody trials used CRO support in 23/42 trials (54.8%). Small-molecule trials used CROs in 77/152 trials (50.7%), monoclonal antibody trials in 62/124 (50.0%), and ADC trials in 13/26 (50.0%).
Advanced modalities do not replace the country and site complexity signal, but bispecific antibody programs show the highest CRO rate among larger modality groups. This likely reflects combined needs for specialist hematology sites, safety oversight, lab infrastructure, and coordinated EU operations.
CRO means contract research organization or a CTIS-listed outsourced clinical-trial support provider. CTIS means Clinical Trials Information System, the EU portal used for clinical trial authorization and country-level Part II submissions. IVRS/IxRS means interactive voice/web response systems used for randomization, treatment allocation, and supply workflows. DLBCL means diffuse large B-cell lymphoma; CLL/SLL means chronic lymphocytic leukemia / small lymphocytic lymphoma; ADC means antibody-drug conjugate.